 SAN DIEGO--BUSINESS WIRE--- ARCT ClinicalTrial--Arcturus Therapeutics Holdings Inc. the Company, Arcturus, Nasdaq: ARCT, a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8, and will also host a conference call and webcast at 